CryoPort (NASDAQ:CYRX) CFO Sells $2,756,577.29 in Stock

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 169,427 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total value of $2,756,577.29. Following the transaction, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at $1,787,259.50. The trade was a 60.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 23rd, Robert Stefanovich sold 1,094 shares of CryoPort stock. The stock was sold at an average price of $8.18, for a total value of $8,948.92.
• On Monday, March 16th, Robert Stefanovich sold 2,743 shares of CryoPort stock. The stock was sold at an average price of $8.00, for a total value of $21,944.00.
• On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The stock was sold at an average price of $7.76, for a total value of $300,312.00.

CryoPort Trading Down 1.4%

CYRX traded down $0.22 on Monday, hitting $15.48. 573,254 shares of the company were exchanged, compared to its average volume of 912,079. The company has a market cap of $780.19 million, a price-to-earnings ratio of 11.47 and a beta of 1.90. The firm has a 50-day moving average price of $11.89 and a two-hundred day moving average price of $10.17. CryoPort, Inc. has a twelve month low of $6.16 and a twelve month high of $16.73.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. Equities analysts expect that CryoPort, Inc. will post -0.85 EPS for the current year.

Institutional Trading of CryoPort

Institutional investors and hedge funds have recently made changes to their positions in the company. Mak Capital One LLC purchased a new stake in CryoPort during the 3rd quarter valued at approximately $7,756,000. UBS Group AG raised its stake in shares of CryoPort by 112.7% during the 3rd quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after buying an additional 705,649 shares in the last quarter. Millennium Management LLC grew its holdings in shares of CryoPort by 23.8% in the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after acquiring an additional 623,896 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in shares of CryoPort by 283.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock worth $4,970,000 after acquiring an additional 387,440 shares during the period. Finally, First Eagle Investment Management LLC acquired a new stake in shares of CryoPort in the 4th quarter worth approximately $2,996,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Needham & Company LLC lifted their price target on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Jefferies Financial Group set a $13.50 price target on CryoPort in a report on Monday. Craig Hallum lifted their price target on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Finally, Guggenheim lifted their price target on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.11.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.